BPC-157

BPC-157 is a 15-amino-acid synthetic peptide studied primarily in laboratory and animal models of vascular, fibroblast, and matrix-response biology.

No single validated human mechanism has been established. Preclinical publications describe interactions with nitric-oxide pathways, vascular signaling, fibroblast activity, growth-factor signaling, and inflammatory mediators.

Predominantly preclinical; credible human evidence remains extremely limited.

Level IV, Predominantly preclinical

Most findings come from animal models and a concentrated group of investigators. Translation to humans, reproducibility, pharmacokinetics, and long-term safety remain unresolved.

Human safety is not established. Immunogenicity, peptide impurities, sterility, dose-response, and proliferative or vascular effects require further evaluation.

No FDA-approved drug product; FDA has cited significant safety-information gaps for compounded BPC-157.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• BPC-157, 5 mgLyophilized
• BPC-157, 10 mgLyophilized
• BPC-157, 500 mcg × 60Capsule
• BPC-157, 1,000 mcg × 60Capsule

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.